Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.277NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.277NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-1638.08US
B.1.277NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-4348.25US
B.1.277NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-1269.64US
B.1.277NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F92.4864US
B.1.277NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-4850.89US
AY.28 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.28 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AY.28 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.28 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.28 (Delta)NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
AY.28 (Delta)NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
AY.28 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
AY.28 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.272NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.272NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-23018.5US
B.1.1.272NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.272NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.272NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.272NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.272NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.272NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.371NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.371NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.1.371NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
B.1.1.371NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-1668.53US
B.1.1.371NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.371NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.371NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.371NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AA.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AA.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
AA.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AA.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AA.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
AA.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
AA.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.353NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-15625.1US
B.1.1.353NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.1.353NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.353NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.353NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
B.1.1.353NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.353NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.353NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.407NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.407NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.407NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.407NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used